National Academies Press: OpenBook

Improving the Quality of Cancer Clinical Trials: Workshop Summary (2008)

Chapter: Appendix B: Workshop Speakers, Moderators, and Invited Discussants

« Previous: Appendix A: Workshop Agenda
Suggested Citation:"Appendix B: Workshop Speakers, Moderators, and Invited Discussants." Institute of Medicine. 2008. Improving the Quality of Cancer Clinical Trials: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12146.
×
Page 123
Suggested Citation:"Appendix B: Workshop Speakers, Moderators, and Invited Discussants." Institute of Medicine. 2008. Improving the Quality of Cancer Clinical Trials: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12146.
×
Page 124

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix B Workshop Speakers,* Moderators,† and Invited Discussants‡ Ken Anderson, M.D., Dana-Farber Cancer Institute* Don Berry, Ph.D., MD Anderson Cancer Center* David Carbone, M.D., Ph.D., Vanderbilt University* David Chang, M.D., Ph.D., Amgen, Inc.‡ Rick Chappell, Ph.D., University of Wisconsin‡ Jerry Collins, Ph.D., National Cancer Institute‡ Robert Comis, M.D., Coalition of National Cancer Cooperative Groups* Janet Dancey, M.D., National Cancer Institute* James Doroshow, M.D., National Cancer Institute*† Giulio Draetta, M.D., Ph.D., Merck Research Laboratories†‡ Susan Ellenberg, Ph.D., University of Pennsylvania* Jeff Evelhoch, Ph.D., Amgen, Inc.*‡ Gwen Fyfe, M.D., Genentech, Inc.* John Gore, Ph.D., Vanderbilt University* Joe Gray, Ph.D., University of California–San Francisco Comprehensive Cancer Center* Steven Gutman, M.D., Food and Drug Administration* Sam Hanash, M.D., Ph.D., Fred Hutchinson Cancer Research Center‡ 123

124 IMPROVING THE QUALITY OF CANCER CLINICAL TRIALS James Heath, Ph.D., California Institute of Technology* Roy Herbst, M.D., Ph.D., MD Anderson Cancer Center*† Hedvig Hricak, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center*† David Jacobson-Kram, Ph.D., Food and Drug Administration* Susan Jerian, M.D., OncoRD, Inc.* Mark Kris, M.D., Memorial Sloan-Kettering Cancer Center* Raju Kucherlapati, Ph.D., Harvard Partners Center for Genetics and Genomics* Steven Larson, M.D., Memorial Sloan-Kettering Cancer Center* Jack Lee, Ph.D., MD Anderson Cancer Center* Pierre Massion, M.D., Vanderbilt University*† Tim McCarthy, Ph.D., Pfizer, Inc.*‡ John Mendelsohn, M.D., MD Anderson Cancer Center*† George Mills, M.D., Parexel International Corporation*† Hal Moses, M.D., Vanderbilt-Ingram Cancer Center* William Pao, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center* David Piwnica-Worms, M.D., Ph.D., Washington University School of Medicine*† Richard Schilsky, M.D., University of Chicago‡ Kevin Schulman, M.D., Duke University Medical School* Lawrence Schwartz, M.D., Memorial Sloan-Kettering Cancer Center* Steven Shak, M.D., Genomic Health, Inc.* Joseph Sparano, M.D., Albert Einstein Comprehensive Cancer Center* Ellen Stovall, National Coalition for Cancer Survivorship* Daniel Sullivan, M.D., Duke University* Daniel Von Hoff, M.D., Translational Genomics Research Institute* John Wagner, M.D., Ph.D., Merck Research Laboratories† Janet Woodcock, M.D., Food and Drug Administration *†

Improving the Quality of Cancer Clinical Trials: Workshop Summary Get This Book
×
Buy Paperback | $46.00 Buy Ebook | $36.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Scientists and clinicians seek a new paradigm that could improve the efficiency, cost-effectiveness, and overall success rate of cancer clinical trials, while maintaining the highest standards of quality. To explore innovative paradigms for cancer clinical trials and other ways to improve their quality, the National Cancer Policy Forum held a workshop, Improving the Quality of Cancer Clinical Trials, in Washington, DC. The main goals of the workshop were to examine new approaches to clinical trial design and execution that would: (1) better inform decisions and plans of those responsible for developing new cancer therapies (2) more rapidly move new diagnostic tests and treatments toward regulatory approval and use in the clinic (3) be less costly than current trials The resulting workshop summary will serve as input to the deliberations of an Institute of Medicine committee that will develop consensus-based recommendations for moving the field of cancer clinical trials forward.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!